Ok_老虎社区_美港股上老虎

AgnesLoh
2021-09-16

DICE Therapeutics spikes 90% on its first day of trading

DICE Therapeutics spikes 90% on its first day of trading. DICE Therapeutics, Inc. (Nasdaq: DICE), a

DICE Therapeutics spikes 90% on its first day of trading

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":885922998,"tweetId":"885922998","gmtCreate":1631752260314,"gmtModify":1631889004232,"author":{"id":4088036751958190,"idStr":"4088036751958190","authorId":4088036751958190,"authorIdStr":"4088036751958190","name":"AgnesLoh","avatar":"https://static.tigerbbs.com/9171f9699090c3ed6c20bfd86a504bd0","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ok</p></body></html>","htmlText":"<html><head></head><body><p>Ok</p></body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/885922998","repostId":2167565687,"repostType":4,"repost":{"id":"2167565687","kind":"news","pubTimestamp":1631725650,"share":"https://www.laohu8.com/m/news/2167565687?lang=&edition=full","pubTime":"2021-09-16 01:07","market":"us","language":"en","title":"DICE Therapeutics spikes 90% on its first day of trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2167565687","media":"StreetInsider","summary":"DICE Therapeutics spikes 90% on its first day of trading.\n\nDICE Therapeutics, Inc. (Nasdaq: DICE), a","content":"<p>DICE Therapeutics spikes 90% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/c6a9e64c65b949f13564eafcd75959a4\" tg-width=\"1398\" tg-height=\"823\" width=\"100%\" height=\"auto\"></p>\n<p>DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced the pricing of its upsized initial public offering of 12,000,000 shares of its common stock at a public offering price of $17.00 per share. All of the shares are being offered by DICE. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by DICE, are expected to be $204.0 million. The shares are expected to begin trading on the Nasdaq Global Market on September 15, 2021 under the ticker symbol “DICE.” The offering is expected to close on September 17, 2021, subject to the satisfaction of customary closing conditions. In addition, DICE has granted the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.</p>\n<p>BofA Securities, SVB Leerink and Evercore ISI are acting as joint bookrunning managers for the offering.</p>\n<p><b>About DICE Therapeutics, Inc.</b></p>\n<p>DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.</p>\n<p><b>Company &amp; Technology</b></p>\n<p>South San Francisco, California-based DICE was founded to leverage its proprietary DELSCAPE platform for discovering and developing chronic immune system disease treatments.</p>\n<p>Management is headed by co-founder and CEO J. Kevin Judice, Ph.D., who has been with the firm since inception and was previously Chief Scientific Officer at Cidara Therapeutics(NASDAQ:CDTX).</p>\n<p>The firm's lead candidate, its oral IL-17 franchise, is being developed to treat psoriasis and other mediated chronic immunology indications.</p>\n<p>Investors in the firm have invested at least $107 million in equity investment and include RA Capital Management, Northpond Ventures and Sands Capital Private Growth.</p>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2019 marketresearch reportby ResearchAndMarkets, the global market for the treatment of psoriasis conditions of all types is expected to reach $46.6 billion by 2022.</p>\n<p>This represents a forecast CAGR (Compound Annual Growth Rate) of 11.5% from 2019 to 2022.</p>\n<p>Key elements driving this expected growth are a rise in incidence of psoriasis among patients possibly attributed to climate changes, increased stress and unhealthy lifestyles.</p>\n<p>Also, according to the World Health Organization, more than 100 million people suffered from some form of psoriasis in 2016.</p>\n<p>Major competitive vendors that provide or are developing related treatments include:</p>\n<ul>\n <li>Novartis(NYSE:NVS)</li>\n <li>Eli Lilly &amp; Co.(NYSE:LLY)</li>\n <li>Bausch Health(NYSE:BHC)</li>\n <li>Amgen(NASDAQ:AMGN)</li>\n <li>Bristol-Myers Squibb(NYSE:BMY)</li>\n <li>Pfizer(NYSE:PFE)</li>\n <li>AbbVie(NYSE:ABBV)</li>\n <li>Nimbus Therapeutics</li>\n <li>Biogen(NASDAQ:BIIB)</li>\n <li>Takeda(NYSE:TAK)</li>\n <li>Boehringer Ingelheim</li>\n <li>Roche(OTCQX:RHHBY)</li>\n</ul>\n<p><b>Financial Status</b></p>\n<p>DICE's recent financial results include little revenue and significant R&amp;D and G&amp;A expenses associated with its development efforts.</p>\n<p>Below are the company's financial results for the past two calendar years:</p>\n<p><img src=\"https://static.tigerbbs.com/e94258a5ab58e3455d45910b28d94828\" tg-width=\"1280\" tg-height=\"780\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, the company had $15.5 million in cash and $8.5 million in total liabilities.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DICE Therapeutics spikes 90% on its first day of trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDICE Therapeutics spikes 90% on its first day of trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-16 01:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18940577><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DICE Therapeutics spikes 90% on its first day of trading.\n\nDICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18940577\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DICE":"DICE Therapeutics, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18940577","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167565687","content_text":"DICE Therapeutics spikes 90% on its first day of trading.\n\nDICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced the pricing of its upsized initial public offering of 12,000,000 shares of its common stock at a public offering price of $17.00 per share. All of the shares are being offered by DICE. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by DICE, are expected to be $204.0 million. The shares are expected to begin trading on the Nasdaq Global Market on September 15, 2021 under the ticker symbol “DICE.” The offering is expected to close on September 17, 2021, subject to the satisfaction of customary closing conditions. In addition, DICE has granted the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.\nBofA Securities, SVB Leerink and Evercore ISI are acting as joint bookrunning managers for the offering.\nAbout DICE Therapeutics, Inc.\nDICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.\nCompany & Technology\nSouth San Francisco, California-based DICE was founded to leverage its proprietary DELSCAPE platform for discovering and developing chronic immune system disease treatments.\nManagement is headed by co-founder and CEO J. Kevin Judice, Ph.D., who has been with the firm since inception and was previously Chief Scientific Officer at Cidara Therapeutics(NASDAQ:CDTX).\nThe firm's lead candidate, its oral IL-17 franchise, is being developed to treat psoriasis and other mediated chronic immunology indications.\nInvestors in the firm have invested at least $107 million in equity investment and include RA Capital Management, Northpond Ventures and Sands Capital Private Growth.\nMarket & Competition\nAccording to a 2019 marketresearch reportby ResearchAndMarkets, the global market for the treatment of psoriasis conditions of all types is expected to reach $46.6 billion by 2022.\nThis represents a forecast CAGR (Compound Annual Growth Rate) of 11.5% from 2019 to 2022.\nKey elements driving this expected growth are a rise in incidence of psoriasis among patients possibly attributed to climate changes, increased stress and unhealthy lifestyles.\nAlso, according to the World Health Organization, more than 100 million people suffered from some form of psoriasis in 2016.\nMajor competitive vendors that provide or are developing related treatments include:\n\nNovartis(NYSE:NVS)\nEli Lilly & Co.(NYSE:LLY)\nBausch Health(NYSE:BHC)\nAmgen(NASDAQ:AMGN)\nBristol-Myers Squibb(NYSE:BMY)\nPfizer(NYSE:PFE)\nAbbVie(NYSE:ABBV)\nNimbus Therapeutics\nBiogen(NASDAQ:BIIB)\nTakeda(NYSE:TAK)\nBoehringer Ingelheim\nRoche(OTCQX:RHHBY)\n\nFinancial Status\nDICE's recent financial results include little revenue and significant R&D and G&A expenses associated with its development efforts.\nBelow are the company's financial results for the past two calendar years:\n\nAs of June 30, 2021, the company had $15.5 million in cash and $8.5 million in total liabilities.","news_type":1},"isVote":1,"tweetType":1,"viewCount":244,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}